Risk Factors Update Summary

• Added compliance details for interactions with health care professionals in foreign countries.
• Detailed the impact of ownership shifts on the expiration of research credits and NOLs.
• Added mention of needing additional funding for European Commission approval, in addition to FDA. This increases financial burden.
• Change in reporting date from 2022 to 2023 for various financial figures, showing recent data.
• Mentioned potential legal challenges to the Medicare drug price negotiation program.
• Noted the potential adverse effects of stock sales triggering limitations under Section 382.
• Discussed the evolving threats, including ransomware attacks, and their potential impacts.
• Net losses decreased from $166.0 million to $111.6 million for the year ended December 31, 2022.
• Revenue generated from Astellas Transactions in 2022, indicating positive financial growth.
• Disclosed changes in the number of employees from 65 to 52 as of December 31, 2023.
• Highlighted the risks associated with data privacy laws and security obligations.
• Cash and cash equivalents increased from $87.9 million to $143.9 million as of December 31, 2022.
• Estimated funding to cover expenses extended from the first quarter of 2024 to 2026.
• Term loan agreement amount reduced from $100 million to $40 million available in a single tranche.